The safety of vaccines has been in the spotlight in recent years following a number of reported incidences relating to the quality of vaccines in China. On 12 October 2020, the National Medical Product Administration (NMPA) released the Administrative Measures for Vaccine Liability Compulsory Insurance which is available for public consultation until 12 November 2020. The draft regulation which, amongst other items, specifies that vaccine marketing licence holders shall be required to take out compulsory vaccine liability insurance for vaccines to be marketed within the territory of the People’s Republic of China.

According to the draft regulation, if disability or death occurs because of the quality of the vaccine, the vaccine market holder will be financially responsible for compensation liability which will be paid to the recipient. In the event of death, the regulation will implement a nationwide uniform minimum liability limit of CNY 500,000 per person. Although companies are encouraged to purchase insurance cover with higher liability limits to cover disability, compensation for disability will be determined based on the injury issued by the disability identification agency.